Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Raised $900 Million in Hong Kong Debut Offering

publication date: Jul 30, 2018

BeiGene, a Beijing oncology company, hopes to raise $1 billion in a debut offering on the Hong Kong stock exchange. The company is already listed on NASDAQ in the US. BeiGene has five drug candidates in clinical trials, and it expects to file NDAs for its two leading candidates in China later this year, including one for a PD-1 molecule. The shares will start trading on August 8. BeiGene reported $1.5 billion in cash at its most recent reporting. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.